Our commitment to transparency
GSK, like most other innovative pharmaceutical companies, engages with healthcare professionals (HCPs) who are considered experts in their field. We believe that it is appropriate to compensate healthcare professionals for their time and investment.
Globally, GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system. Transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines and improve clinical practice and care for patients.
We are pioneers
GSK and ViiV Healthcare initiated voluntary disclosure of aggregate payments made to HCPs and HCOs in 2017. We have since expanded reporting to include payments to individual HCPs and HCP professional corporations.
The important relationship between industry and HCPs
The relationship between healthcare companies and HCPs is an essential part of patient care, disease understanding, as well as the research and discovery of innovative medicines in Canada. By continuing to be transparent on these relationships, we are evolving with society’s expectations.
In Scope Activities
GSK engages with HCPs and HCOs to foster scientific exchange, which benefits patients. These interactions are governed by law and regulated by Innovative Medicines Canada’s Code of Ethical Practices (PDF - 1.6 MB).
What are payments or transfers of value (TOV)?
We are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services and virtual registration fees. Additionally, payments made to HCP professional corporations will be disclosed under the name of the professional corporation.
Of note, payments do not include where an HCP has withdrawn their consent to disclose this information.
What are the collaborations for?
- Grants to HCOs
- Training activities and scientific professional meetings
- R&D activities
- Provision of services such as consulting
What does individual disclosure mean?
We are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services and virtual registration fees. Additionally, payments made to HCP professional corporations will be disclosed under the name of the professional corporation.
Of note, payments do not include where an HCP has withdrawn their consent to disclose this information.
GSK’s voluntary decision to publish our payments to HCPs and HCOs is part of our commitment to greater transparency and high ethical standards in our business practices. The “Voluntary Framework on Disclosure” was developed by Innovative Medicines Canada.
Aggregate payments (one sum total)
$2,463,920.60*
TOV to HCPs
$12,362,318
TOV to HCOs
*View a breakdown of individual payments made to HCPs.
*View a breakdown of payments made to HCP Professional Corporations
Other figures
$955,668,000
2022 GSK in Canada Sales
(Total Payments to HCPs and HCOs represent 1.55% of Sales)
$1,133,500
2022 Community Groups Grants and Donations
GSK also provides and publishes funding made to patient groups.
For clarity purposes only, please note the following:
- Applicable taxes may be included or excluded.
- The amounts provided may include certain related incidental expenses (such as, but not limited to, mileage reimbursement for travel).
- HCPs engaged by GSK who appear in the individual payments section have consented to disclosure of their names and payments. Pursuant to Canadian privacy law, consent to the individual disclosure of information may be withdrawn at any time.
- GSK has used its reasonable best efforts to capture the most comprehensive data possible according to its knowledge and interpretation of the Voluntary Framework of Payments to HCPs/HCOs.
NOTE: While GSK makes every effort to present accurate and reliable information, GSK makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. GSK shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by GSK or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and GSK is not responsible for the contents of or the availability of access to such websites.
2021
View the 2021 Transparency Report
2020
View the 2020 Transparency Report
2019
View the 2019 Transparency Report
2018
View the 2018 Transparency Report (PDF - 383 KB)
2017
View the 2017 Transparency Report (PDF - 378 KB)
2016
View the 2016 Transparency Report (PDF - 327 KB)
